ArticleAmerican journal of translational research2025
Association between elevated maternal serum MSX1 and IRF6 levels and fetal orofacial clefts: implications for clinical prediction.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the association between maternal serum expression levels of Msh homeobox 1 (MSX1) and interferon regulatory factor 6 (IRF6) and fetal cleft lip and palate (CLP), as well as their potential role in clinical prediction.
methodsA prospective case-control study was conducted. A total of 100 pregnant women carrying fetuses diagnosed with CLP via prenatal screening and diagnosis at The Affiliated Women and Children's Hospital of Ningbo University from July 2021 to June 2024 (CLP group) and 105 pregnant women with healthy fetuses (normal group) were selected as the research subjects. Clinical data and relative expression levels of MSX1 and IRF6 were collected. Binary logistic regression was used to analyze the influencing factors of fetal CLP. A Gradient Boosting Machine (GBM) model was developed using R language 4.4.1 software to predict fetal CLP and evaluate its predictive performance.
resultsThe serum levels of MSX1 and IRF6 in the CLP group were higher than those in the normal group (t = 6.536, 9.907; both P < 0.001). Independent influencing factors for fetal CLP included maternal age, family history of CLP, malnutrition during pregnancy, and expression of MSX1 and IRF6. A GBM model was constructed based on these factors, with their relative importance ranked as follows: IRF6 > MSX1 > family history of CLP > maternal malnutrition > age. In the training set, the GBM model achieved an area under the curve (AUC) of 0.898 (95% CI: 0.849, 0.948), with a sensitivity of 79.2% and specificity of 88.7%. In the validation set, the AUC was 0.895 (95% CI: 0.818, 0.973), with sensitivity of 85.7% and the specificity of 82.4%. The calibration curve demonstrated good agreement between predicted and actual probabilities. Decision curve analysis showed a threshold probability range of 0.30-0.72 in the training set and 0.30-0.73 in the validation set.
conclusionElevated maternal serum MSX1 and IRF6 expression levels are closely associated with fetal CLP and may serve as potential biomarkers for its clinical prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.